On Friday, SpyGlass Pharma Inc (SGP.US) commenced trading on the US stock market. The stock opened sharply higher, surging more than 43% to $23 per share, compared to its IPO price of $16. SpyGlass Pharma is a late-stage clinical biotechnology company focused on developing sustained drug delivery systems for chronic ocular diseases. The company aims to enhance patient vision and quality of life through longer-acting and more sustainable treatment options. Its core research and development product includes a system that integrates a drug delivery insert with an intraocular lens, designed to treat chronic eye conditions such as open-angle glaucoma or ocular hypertension. This type of therapy seeks to improve efficacy and patient adherence, offering potential advantages over traditional daily eye drop regimens.